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1Among patients with atrial fibrillation (AF), women tend to be at higher risk of stroke than men,1–6 even after adjust-
ment for baseline comorbid conditions and vitamin K antago-
nist treatment.7,8 Female sex has therefore been incorporated 
in stroke risk stratification schemes, such as CHA2DS2-VASc 
(Cardiac failure or dysfunction, Hypertension, Age ≥75 
[Double], Diabetes, Stroke [Double]-Vascular disease, Age 
65–74, and Sex category [Female]),9 and is specified in inter-
national guidelines for stroke prevention in AF.10–12
Women have a longer life expectancy than men and there-
fore comprise a larger proportion of the elderly population 
who are at risk of stroke caused by AF.13 As such, women rep-
resent an important target for preventive strategies. Women 
are under-represented in mixed-sex cardiovascular trials, 
resulting in a deficit of information on differences in treatment 
effect and in side-effect profiles.14
Using data from a large contemporary prospective cohort 
study of patients newly diagnosed with non-valvular AF, we 
investigated the use of anticoagulants for stroke prevention in 
women and men, according to validated stroke and bleeding 
risk stratification schemes: CHADS2 (Congestive heart fail-
ure, Hypertension, Age >75 years, Diabetes mellitus, and prior 
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Stroke or transient ischemic attack [Double]),15 CHA2DS2-
VASc,9 and HAS-BLED (Hypertension, Abnormal renal/
liver function, Stroke, Bleeding history or predisposition, 
Labile international normalized ratio [INR], Elderly, Drugs/
alcohol concomitantly).16 We hypothesized that anticoagulant 
use in women would be lower than that in men using data 
from the Global Anticoagulant Registry in the FIELD-Atrial 
Fibrillation (GARFIELD-AF).
Methods
Design
GARFIELD-AF is an ongoing, observational, worldwide study of 
adults with recently diagnosed nonvalvular AF.17
Independent ethics committee and hospital-based institutional 
review board approvals were obtained, as necessary, for the reg-
istry protocol. The registry is being conducted in accordance with 
the principles of the Declaration of Helsinki, local regulatory re-
quirements, and the International Conference on Harmonisation-
Good Pharmacoepidemiological and Clinical Practice Guidelines. 
All patients provided written informed consent to participate. 
Confidentiality and anonymity of all patients enrolled into this regis-
try are maintained at all times.
Study Population
Men and women aged ≥18 years with nonvalvular AF diagnosed ac-
cording to standard local procedures within the past 6 weeks and with 
≥1 additional factor(s) for stroke as judged by the investigator were 
eligible for enrollment.17 These risk factors were not prespecified in 
the protocol nor were they limited to the components of existing risk 
stratification schemes. Patients with a transient reversible cause of AF 
and those for whom follow-up to 2 years was unlikely were excluded. 
Data were collected using an electronic case report form.17 Patient en-
rollment was consecutive. Patients are being enrolled prospectively 
into 5 subsequent cohorts, each comprising ≈10 000 patients.17 Cohort 
1 included a validation cohort of 5000 patients, enrolled at the same 
time as the first cohort, to describe the nature and characteristics of care 
for patients at participating sites before registry initiation; these pa-
tients were enrolled retrospectively and were excluded from the pres-
ent analysis. This article reports only cross-sectional data at baseline.
Study Sites
A 3-step process was used for site selection to ensure proportional 
representation of the spectrum of care settings in each country. First, 
the national coordinating investigator identified the care settings, 
including office-based practice, hospital departments (neurology, 
cardiology, geriatrics, internal medicine, and emergency), antico-
agulation clinics, and general or family practices, they believed most 
accurately represented the management of AF patients in their coun-
try. Second, the contract research organization provided a list (sam-
pling frame) of sites from various database searches that reflected 
the care settings in the country. Third, the contract research orga-
nization contacted a random (ie, lack of selection of sites based on 
specific criteria rather than using random sampling) sample of sites 
for each care setting from the list, in accordance with the distribution 
specified by the national coordinating investigator. Sites that agreed 
to participate were recruited after a qualification telephone call, and 
the relevant investigator was required to complete a program provid-
ing guidance on patient screening, enrollment, and follow-up in the 
registry.
Data
Registry data were captured by trained data abstractors in electron-
ic case report forms (designed by Dendrite Clinical Systems Ltd, 
Henley-on-Thames, United Kingdom, which is also responsible for 
ongoing database program management). Data collection and entry 
are managed by Quintiles (Durham, NC), which oversees all opera-
tional aspects of the program, apart from in the United Kingdom, 
where the tasks are undertaken by The University of Birmingham 
Department of Primary Care Clinical Sciences. Submitted data are 
examined by the coordinating center (Thrombosis Research Institute, 
London, United Kingdom) to ascertain their completeness and ac-
curacy, and data queries are sent to participating sites. Data for this 
analysis, extracted on February 3, 2014, were analyzed by a statisti-
cian (Gabriele Accetta). The GARFIELD-AF registry uses a combi-
nation of techniques for quality control in monitoring of this study: 
frequent electronic database monitoring of all data entered into the 
registry database; remote site monitoring by clinical research associ-
ates on a monthly, quarterly, or 6-monthly basis depending on the 
site; on-site monitoring, which includes source document verification 
as per the monitoring plan; and ongoing monitoring of quality by the 
Audit Committee (Data Supplement).
Definitions
The term anticoagulation encompasses vitamin K antagonists, oral, 
injectable or undefined factor Xa inhibitors, and direct thrombin in-
hibitors. Vascular disease was defined as peripheral artery disease or 
coronary artery disease with a history of acute coronary syndrome 
(unstable angina or myocardial infarction). Hypertension was defined 
as a documented history of hypertension or blood pressure >140/90 
mm Hg.
Statistical Analysis
Continuous variables are expressed as mean±SD or median (inter-
quartile range) and categorical variables as frequency and percentage. 
Reported use at baseline of antithrombotic therapies was analyzed 
in relation to sex, according to CHADS2,15 CHA2DS2-VASc,9 and 
modified HAS-BLED (excluding fluctuations in the international 
normalized ratio) scores, calculated retrospectively from the data 
provided.16 For patients with a CHADS2 score of ≥2, the strength of 
the association between independent factors and use of anticoagula-
tion is expressed using odds ratios (ORs). Uncertainty related to OR 
estimates was assessed using 95% confidence intervals. Logistic re-
gression models with only one independent factor as the explanatory 
variable in each were fitted to estimate crude ORs (univariate mod-
els). Adjusted ORs were estimated using a multivariable model. The 
models included variables judged to be of clinical relevance: sex, age, 
previous stroke, history of hypertension, congestive heart failure, dia-
betes mellitus, vascular disease, and geographic region. HAS-BLED 
WHAT IS KNOWN
•	 Women with atrial fibrillation are at higher risk of 
stroke than men with atrial fibrillation.
•	 The reasons for this elevated risk remain unclear, 
but they may include older age of women, use of 
 hormone replacement therapy, undertreatment or 
suboptimal management with a vitamin K antago-
nist, and poor anticoagulation control.
WHAT THE STUDY ADDS
•	 The results from our worldwide study suggest that 
women are treated no differently to men in terms of 
anticoagulant therapy for stroke prevention.
•	 Thromboprophylaxis was, however, suboptimal in 
substantial proportions of men and women, with 
underuse in those at moderate-to-high risk of stroke 
and overuse in those at low risk.
•	 Improvements in anticoagulation prescription and 
management are needed for women and men.
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was not included in the models because of a high number of miss-
ing values. Patients with any missing values for confounders or un-
known anticoagulant use did not contribute to the models. Age was 
categorized into 5 groups: ≤55, >55 to ≤65, >65 to ≤75, >75 to ≤85, 
and >85 years. Three different regions were included in the mod-
els: Europe (Austria, Belgium, Czech Republic, Denmark, Finland, 
France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, 
Russia, Spain, Sweden, Ukraine, and United Kingdom), Asia (China, 
India, Japan, Korea, Singapore, and Thailand), and non-Europe/non-
Asia (Argentina, Australia, Brazil, Canada, Chile, Mexico, and South 
Africa). All other variables were treated as dichotomous, having only 
2 possible values of yes and no. Adjusted ORs for risk factors were 
compared between women and men, fitting a model with first-degree 
interaction between sex and all other factors. Data analysis was per-
formed with SAS statistical software, release 9.4 (SAS Institute Inc, 
Cary, NC).
Results
Study Population
Enrollment took place at 858 randomly selected sites in 30 
countries in Europe (n=10 851; 63.1%), Asia (n=3949; 23.0%), 
Central/South America (n=1443; 8.4%), Canada (n=348; 
2.0%), Australia (n=427; 2.5%), and South Africa (n=166; 
1.0%) between March 2, 2010, and June 7, 2013 (Table 1). 
Baseline characteristics for the 17 184 patients are shown 
in Table 2. Of this population, 7530 (43.8%) were women. 
Women were older than men, with 47.5% aged ≥75 years ver-
sus 30.6% of men, and were less likely to be current or past 
smokers or heavy alcohol drinkers and to have coronary artery 
disease, peripheral artery disease, or a left ventricular ejec-
tion fraction of <40%. Women had higher prevalences of his-
tory of hypertension and moderate renal disease (ie, estimated 
glomerular filtration rate of 30–59 mL/min) and higher mean 
CHA2DS2-VASc scores because of their sex. A greater pro-
portion of the women were at moderate-to-high risk of stroke 
(CHADS2 score of ≥2: 65.1% versus 54.7% of men). Almost 
all of the women (97.3%) had a CHA2DS2-VASc score of ≥2 
versus 77.1% of the men. Of the 10 882 patients in whom the 
HAS-BLED score could be calculated, 12.3% of men and 
14.1% of women had a score of ≥3; the mean scores were 
similar in men and women.
Antithrombotic Therapy Use in Men and Women 
Overall and According to Risk Scores
Antithrombotic drugs given at diagnosis of AF are detailed 
in Table 3 and Figure 1. Aspirin was given to >30% of 
both men and women and adenosine diphosphate recep-
tor inhibitors/P2Y12 inhibitors to 8.0% of men and 6.2% 
of women. Overall rates of anticoagulant use were no 
different in men and women (5788/9509 [60.9%] versus 
4498/7404 [60.8%], respectively; Figure 1); 11.8% of men 
and 11.7% of women were receiving a factor Xa inhibitor 
or direct thrombin inhibitor (Table 3). Twenty-eight percent 
of men and 27.2% of women received an antiplatelet alone, 
and 12% of both men and women received no antithrom-
botic therapy. When analyzed by the level of stroke risk, 
approximately half of the men and women at low risk of 
stroke received some form of anticoagulant therapy, with 
similar patterns of antithrombotic use in men and women 
(Figure 2A). Among those with a CHADS2 score of 1, men 
had slightly higher levels of anticoagulant use compared 
with women. In patients with a CHADS2 score of ≥2, men 
were more likely than women to receive the combination 
of anticoagulant plus antiplatelet, but the overall rates of 
anticoagulant use were similar. After adjustment, use of 
an anticoagulant for stroke prevention in patients with a 
CHADS2 score of ≥2 was the same in women and men (OR, 
1.00; 95% confidence interval, 0.92–1.09).
In patients with a low risk of stroke, 41.8% (158/378) of 
men (CHA2DS2-VASc score of 0) and 41.1% (81/197) of 
women (CHA2DS2-VASc score of 1) received an antico-
agulant (Figure 2B); the rate of antiplatelet use alone was 
slightly higher in women. In patients at high risk of stroke 
(CHA2DS2-VASc score of ≥2), 64.6% (4593/7108) of men 
and 61.6% (4329/7032) of women received an anticoagulant, 
Table 1. Global Anticoagulant Registry in the FIELD-Atrial 
Fibrillation Population by Region and Country (n=17 184)
Region/Country
Patients Enrolled
n %
Asia 3949 23.0
  China 946 5.5
  India 318 1.9
  Japan 827 4.8
  Korea 1595 9.3
  Singapore 70 0.4
  Thailand 193 1.1
Central/South America 1443 8.4
  Argentina 306 1.8
  Brazil 345 2.0
  Chile 181 1.1
  Mexico 611 3.6
Europe 10 851 63.1
  Austria 271 1.6
  Czech Republic 524 3.0
  Belgium 403 2.3
  Denmark 252 1.5
  Finland 216 1.3
  France 725 4.2
  Germany 1837 10.7
  Hungary 340 2.0
  Italy 982 5.7
  The Netherlands 518 3.0
  Norway 117 0.7
  Poland 1104 6.4
  Russia 526 3.1
  Spain 1070 6.2
  Sweden 538 3.1
  Ukraine 529 3.1
  United Kingdom 899 5.2
Other countries 941 5.5
  Australia 427 2.5
  Canada 348 2.0
  South Africa 166 1.0
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with or without an antiplatelet, whereas combination therapy 
with anticoagulant plus antiplatelet was more frequent in men 
(Figure 2B).
The use of antithrombotic drugs according to bleeding risk 
stratum is shown in Figure 3. Of the 17 184 patients, 6302 
(36.7%) had values missing for components of the HAS-
BLED score. Similar patterns of use were observed when 
comparing men with women, in both the low-risk (HAS-
BLED score of 0–2) and high-risk (HAS-BLED score of ≥3) 
groups. The overall rate of use of anticoagulants was higher 
in patients at low risk of bleeding (3346/5203 [64.3%] men 
and 2694/4087 [65.9%] women) when compared with those 
at high risk (377/729 [51.7%] and 349/673 [51.9%], respec-
tively). Both men and women at high risk of bleeding were 
more likely than those at low risk to receive combination anti-
thrombotic therapy or antiplatelet therapy alone.(Continued )
Table 2. Baseline Characteristics in Men and Women With 
Nonvalvular Atrial Fibrillation (n=17 184)
Variable Men (n=9654) Women (n=7530)
Age
  Mean (SD), y 68/9654 (12) 73/7530 (10)
Age group, n (%)
  <65 y 3560/9654 (36.9) 1550/7530 (20.6)
  65–74 y 3144/9654 (32.6) 2400/7530 (31.9)
  ≥75 y 2950/9654 (30.6) 3580/7530 (47.5)
Body mass index
  Missing data, n (%) 1809 (18.7) 1619 (21.5)
  Mean (SD), kg/m2 27.7 (4.97) 27.8 (5.92)
Current/previous smoker, n (%) 4378/8748 (50.0) 1097/6898 (15.9)
Pulse
  Missing data, n (%) 914 (9.5) 670 (8.9)
  Median (IQR), bpm 82.0 (70.0–100.0) 85.0 (70.0–110.0)
Systolic blood pressure
  Missing data, n (%) 667 (6.9) 544 (7.2)
  Median (IQR), mm Hg 130.0 (120.0–144.0) 134.0 (120.0–148.0)
Diastolic blood pressure
  Missing data, n (%) 667 (6.9) 544 (7.2)
  Median (IQR), mm Hg 80.0 (70.0–89.0) 80.0 (70.0–88.0)
Heavy alcohol consumption, n (%)* 349/8258 (4.2) 28/6494 (0.4)
Medical history, n (%)
  Acute coronary syndromes 1103/9652 (11.4) 520/7527 (6.9)
  Bleeding 292/9649 (3.0) 203/7526 (2.7)
  Carotid occlusive disease 294/9649 (3.0) 207/7526 (2.8)
  Chronic renal disease
   Missing data 2544/7110 (26.4) 1845/5685 (24.5)
   Mild renal dysfunction, GFR, 
60–89 mL/min
1401/7110 (19.7) 1116/5685 (19.6)
   Moderate renal dysfunction, 
GFR, 30–59 mL/min
754/7110 (10.6) 751/5685 (13.2)
   Severe renal dysfunction, 
GFR, <30 mL/min
133/7110 (1.9) 121/5685 (2.1)
  Cirrhosis 63/9648 (0.7) 30/7527 (0.4)
  Congestive heart failure 1955/9653 (20.3) 1588/7529 (21.1)
  Coronary artery disease 2150/9653 (22.3) 1270/7529 (16.9)
  Coronary artery bypass graft 
surgery
407/8319 (4.9) 100/6425 (1.6)
  Diabetes mellitus 2127/9653 (22.0) 1634/7529 (21.7)
  Family history of premature 
cardiac disease†
1666/8008 (20.8) 1379/6219 (22.2)
  Hypercholesterolemia 3790/9648 (39.3) 3090/7528 (41.0)
  History of hypertension 7303/9653 (75.7) 6114/7529 (81.2)
  Left ventricular ejection fraction 
<40%
734/5638 (13.0) 247/4125 (6.0)
  Peripheral artery disease 719/9648 (7.5) 406/7526 (5.4)
  Pulmonary embolism or DVT 221/9651 (2.3) 255/7526 (3.4)
  Stroke or TIA 1185/9653 (12.3) 993/7529 (13.2)
  Stroke 811/9652 (8.4) 640/7526 (8.5)
  Systemic embolism 59/9652 (0.6) 52/7525 (0.7)
Table 2. Continued
Variable Men (n=9654) Women (n=7530)
  Other thromboembolism‡ 99/9593 (1.0) 81/7470 (1.1)
  Hormone replacement therapy 35/9654 (0.4) 119/7530 (1.6)
Risk score
  CHADS
2
   Missing data, n (%) 229 (2.4) 128 (1.7)
   Mean (SD) 1.8 (1.1) 2.0 (1.1)
   Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0)
   0, n (%) 735/9425 (7.8) 383/7352 (5.2)
   1, n (%) 3538/9425 (37.5) 2197/7352(29.7)
   ≥2, n (%) 5152/9425 (54.7) 4822/7352 (65.1)
  CHA
2
DS
2
-VASc
   Missing data, n (%) 281 (2.9) 178 (2.4)
   Mean (SD) 2.7 (1.5) 4.0 (1.5)
   Median (IQR) 3.0 (2.0–4.0) 4.0 (3.0–5.0)
   0, n (%) 381/9373 (4.1) …
   1, n (%) 1769/9373 (18.9) 200/7352 (2.7)
   ≥2, n (%) 7223/9373 (77.1) 7152/7352 (97.3)
  HAS-BLED§
   Missing data, n (%) 3616 (37.5) 2686 (35.7)
   Mean (SD) 1.4 (0.9) 1.5 (0.9)
   Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
   0–2, n (%) 5295/6038 (87.7) 4159/4844 (85.9)
   ≥3, n (%) 743/6038 (12.3) 685/4844 (14.1)
CHA
2
DS
2
-VASc indicates cardiac failure or dysfunction, hypertension, 
age ≥75 [double], diabetes mellitus, stroke [double]-vascular disease, age 
65–74, and sex category [female]; CHADS
2
 indicates congestive heart failure, 
hypertension, age >75 years, diabetes mellitus, and previous stroke or transient 
ischemic attack [double]; DVT, deep vein thrombosis; GFR, glomerular filtration 
rate; HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding 
history, or predisposition, labile international normalized ratio, elderly, drugs/
alcohol concomitantly; IQR, interquartile range; and TIA, transient ischemic 
attack.
*Investigator-defined.
†First-degree relative with premature cardiac history (age <55 y [men]; 
<65 y [women]).
‡For example, central venous thrombosis and retinal occlusion.
§Excluding international normalized ratio fluctuations.
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The main reasons for not giving an anticoagulant to patients 
at moderate-to-high risk of stroke (CHADS2 score of ≥2) were 
similar between men and women and were largely because of 
physician choice (Table 4).
Anticoagulant Use in Subgroups at Risk of Stroke
The univariate ORs for anticoagulant use in various subgroups 
of patients with a CHADS2 score of ≥2 are provided in Table 5, 
and the adjusted data for men and for women are presented in 
Figure 4. After adjustment, patients aged ≥85 years appeared 
to have a lower rate of use of anticoagulants than those aged 
≤55 years, but the difference was not significant. Anticoagu-
lant use was decreased in men and women aged ≥85 years. 
Men and women with a previous stroke were more likely than 
those without to receive anticoagulant treatment, whereas men 
and women with a history of hypertension were less likely to 
receive anticoagulants than those without a history.
Discussion
In this large, contemporary, prospective, global cohort study 
of patients with newly diagnosed nonvalvular AF, overall use 
of anticoagulant therapy for stroke prevention was no differ-
ent in men and women. Among patients with a CHADS2 score 
of 1, women were less likely than men to receive combina-
tion antithrombotic therapy. Use of anticoagulants in patients 
with a CHADS2 score of 0 could reflect suboptimal adherence 
Table 3. Use of Antithrombotic Drugs at Diagnosis in Men 
and Women With Nonvalvular Atrial Fibrillation (n=17 184)
Variable Men (n=9654) Women (n=7530)
Antiplatelet, n (%)*
  Aspirin 3279 (34.0) 2357 (31.3)
  Adenosine diphosphate receptor or 
P2Y
12
 inhibitor
772 (8.0) 468 (6.2)
  Glycoprotein IIb/IIIa inhibitor 
(abciximab, eptifibatide, and 
tirofiban)
29 (0.3) 16 (0.2)
  Prostaglandin analog 17 (0.2) 8 (0.1)
Anticoagulant, n (%)*
  Vitamin K antagonist 4867 (50.4) 3770 (50.1)
  Factor Xa inhibitor 627 (6.5) 469 (6.2)
  Direct thrombin inhibitor 514 (5.3) 411 (5.5)
  Heparinoid 97 (1.0) 59 (0.8)
  Unfractionated or low-molecular 
weight heparin
939 (9.7) 776 (10.3)
  Other 56 (0.6) 29 (0.4)
*Categories are not mutually exclusive.
Figure 1. Antithrombotic use (including 460 patients on injectable 
or undefined factor Xa or direct thrombin inhibitor treatment) 
for stroke prevention in men and women with nonvalvular atrial 
fibrillation. AP indicates antiplatelet; DTI, direct thrombin inhibitor; 
factor Xa, factor Xa inhibitor; and VKA, vitamin K antagonist.
A
B
Figure 2. Antithrombotic use (including 460 patients on 
injectable or undefined factor Xa or direct thrombin inhibitor 
treatment) for stroke prevention according to (A) CHADS2 and 
(B) CHA2DS2-VASc scores in men and women with nonvalvular 
atrial fibrillation. AP indicates antiplatelet; DTI, direct thrombin 
inhibitor; factor Xa, factor Xa inhibitor; and VKA, vitamin K 
antagonist.
Figure 3. Antithrombotic use (including 460 patients on 
injectable or undefined factor Xa or direct thrombin inhibitor 
treatment) according to HAS-BLED score (excluding international 
normalized ratio fluctuations) in men and women with nonvalvular 
atrial fibrillation. AP indicates antiplatelet; DTI, direct thrombin 
inhibitor; factor Xa, factor Xa inhibitor; and VKA, vitamin K 
antagonist.
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to guidelines, or it may simply indicate that many clinicians 
think a CHADS2 score of 0 is not low risk18 and informally 
consider other risk factors when assessing risk. Among truly 
low-risk patients (CHA2DS2-VASc score of 0 in men and 1 
in women), who are not considered candidates for anticoagu-
lant therapy according to the guidelines,10,12 ≈40% received 
an anticoagulant. In contrast, among those with a CHA2DS2-
VASc score of ≥2, in whom anticoagulation is a class I rec-
ommendation, one-third did not receive an anticoagulant. Of 
the women with a CHA2DS2-VASc score of 0, 41.1% were 
prescribed anticoagulants (some in combination with an anti-
platelet) and 34.5% received an antiplatelet alone. Only 24.4% 
received no antithrombotic therapy, consistent with guideline 
recommendations.10 The high rate of use of antiplatelet ther-
apy does not correlate with the rates of cardiovascular diseases 
among women, indicating that antiplatelets are still being 
given to low-risk women for stroke prevention, thus increas-
ing bleeding risk. Similarly, 41.8% of men with a CHA2DS2-
VASc score of 0 were prescribed anticoagulant therapy, and 
only 28.3% received no antithrombotic therapy. These find-
ings of suboptimal thromboprophylaxis are of concern and 
indicate the need for improved stroke prevention in AF. These 
observations were evident from registries conducted a decade 
ago19–21 and show that anticoagulant use remains suboptimal 
in both sexes, reflecting the many limitations and difficulties 
with using vitamin K antagonists, and despite the recent intro-
duction of direct anticoagulants.
Estimating bleeding risk in patients with AF can be dif-
ficult. The use of risk scores, such as HAS-BLED, may 
help clinicians make an informed decision about a patient’s 
potential risk for bleeding. In this study, the patterns of use 
of antithrombotic therapy were broadly similar when compar-
ing men with women at low or at high risk of a bleed. The 
overall rates of anticoagulant therapy were higher in the low-
risk group. However, combination antithrombotic therapy 
was more frequent in the high-risk group. Although the use 
of more intensive therapy in such patients may be somewhat 
unexpected, given that it is associated with an increased risk 
of bleeding complications,22 it probably reflects overlapping 
risk factors in stroke and bleeding risk scores. The presence of 
comorbid conditions such as coronary artery disease cannot, 
alone, account for the high rates of use of combination therapy 
in men and women at high risk of bleeding. Furthermore, a 
high HAS-BLED score per se should not be used to withdraw 
or preclude the use of anticoagulants; rather, it should be used 
to identify patients at higher risk of bleeding and to correct 
any potentially reversible risk factors for this event,10 and, in 
particular, to reconsider the use of combination antithrom-
botic therapy.
Reasons for the increased risk of stroke in women are 
uncertain. Stroke risk may be age dependent because, com-
pared with that in men, it is increased only in women ≥65 
years of age.23 Hormone replacement therapy may be a risk 
factor for ischemic stroke.24 Undertreatment or suboptimal 
management with an oral anticoagulant is also a possibility, 
with poor average time in the therapeutic range25 and frequent 
interruptions in anticoagulant therapy8 possibly contributing 
to the higher risk of stroke in women. The ORs for anticoagu-
lant use in subgroups of men and women were similar, with 
the exception of men with a previous stroke or aged 65 to 75 
years who were more likely to receive anticoagulants, whereas 
women with congestive heart failure and men with a history of 
hypertension were less likely to receive anticoagulants.
The GARFIELD-AF data show some similarities with the 
Euro Heart Survey on AF,26 which was conducted between 
2003 and 2004, and involved 5333 patients with AF from 35 
European Society of Cardiology countries. Although the use 
of anticoagulants in men and women was similar, several dif-
ferences were apparent: women were older than men and had 
a higher prevalence of comorbid conditions. Men and women 
in the GARFIELD-AF registry were, however, older (68 and 
73 years, respectively) than those in the Euro Heart Survey on 
AF (64 and 70 years, respectively), and they had a lower prev-
alence of congestive heart failure and coronary artery disease 
but a higher prevalence of hypertension and previous stroke, 
suggesting temporal, ascertainment, and geographic differ-
ences between these study populations.
The prospective GARFIELD-AF registry is the largest world-
wide initiative to study the risk of stroke among patients with 
newly diagnosed nonvalvular AF. The present analysis includes 
data spanning 30 countries across 6 continents. The population 
is representative of the spectrum of patients treated in every-
day practice in each of the countries. This analysis is, however, 
limited by its observational design, although great efforts were 
made to standardize definitions of conditions, and missing data. 
No information has been included on race. The percentage of 
low-risk patients who were overtreated may have been overes-
timated, as the primary indication for anticoagulant use was not 
recorded, no data were available for patients with a mechani-
cal heart valve, and history of cardioversion or ablation was 
known for few patients (146 and 152, respectively). Of the low-
risk patients (CHADS2 score of 0), only 10 men and 5 women 
had a history of venous thromboembolism. Recruitment pre-
ceded publication of the European Society of Cardiology 2010 
guidelines27 on stroke prevention, which suggests the use of 
Table 4. Main Reasons Why Vitamin K Antagonists Were Not 
Given to Men and Women With a CHADS2 Score of ≥2 (n=2643)
Reason, n (%) Men (n=1349) Women (n=1294)
Physician’s choice 625 (46.3) 639 (49.4)
  Bleeding risk 111 (17.8) 94 (14.7)
  Concern over patient compliance 71 (11.4) 67 (10.5)
  Guideline recommendation 15 (2.4) 20 (3.1)
  Fall risk 49 (7.8) 123 (19.2)
  Low risk of stroke 67 (10.7) 52 (8.1)
  Not specified 312 (49.9) 283 (44.3)
Patient refusal 119 (8.8) 112 (8.7)
Already taking antiplatelet drugs for 
other medical conditions
91 (6.7) 68 (5.3)
Previous bleeding event 26 (1.9) 25 (1.9)
Alcohol misuse 13 (1.0) 2 (0.2)
Taking medication contraindicated 
or cautioned for use with vitamin K 
antagonist or anticoagulants
7 (0.5) 6 (0.5)
Other or unknown 468 (34.7) 442 (34.2)
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the CHA2DS2-VASc score to determine stroke risk. The results 
for the HAS-BLED score should be interpreted with caution 
because of the high number of missing values.
Conclusions
Overall rates of anticoagulant use in nonvalvular AF are no 
different in men and women. The results indicate subopti-
mal application of thromboprophylaxis in large proportions 
of men and women with AF, with underuse in moderate-to-
high-risk patients and overuse in low-risk patients. Improve-
ments in stroke prevention, as well as stroke and bleeding risk 
assessment, are clearly needed in men and women with AF.
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